Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDXS NASDAQ:GERN NASDAQ:RIGL NASDAQ:ZBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDXSCodexis$2.42$2.82$1.90▼$6.08$218.45M2.541.40 million shs722,273 shsGERNGeron$1.40+1.4%$1.34$1.09▼$4.83$893.22M0.637.86 million shs5.10 million shsRIGLRigel Pharmaceuticals$41.34+3.0%$28.25$12.66▼$43.72$741.52M1.27849,943 shs465,960 shsZBIOZenas BioPharma$20.51+20.8%$14.73$5.83▼$26.25$863.68MN/A171,278 shs571,756 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDXSCodexis0.00%-11.36%-15.38%+2.11%-14.49%GERNGeron+1.45%0.00%+1.08%-12.50%-67.37%RIGLRigel Pharmaceuticals+3.02%+6.41%+38.68%+92.37%+213.66%ZBIOZenas BioPharma+20.79%+28.19%+30.64%+84.44%+2,050,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDXSCodexis$2.42$2.82$1.90▼$6.08$218.45M2.541.40 million shs722,273 shsGERNGeron$1.40+1.4%$1.34$1.09▼$4.83$893.22M0.637.86 million shs5.10 million shsRIGLRigel Pharmaceuticals$41.34+3.0%$28.25$12.66▼$43.72$741.52M1.27849,943 shs465,960 shsZBIOZenas BioPharma$20.51+20.8%$14.73$5.83▼$26.25$863.68MN/A171,278 shs571,756 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDXSCodexis0.00%-11.36%-15.38%+2.11%-14.49%GERNGeron+1.45%0.00%+1.08%-12.50%-67.37%RIGLRigel Pharmaceuticals+3.02%+6.41%+38.68%+92.37%+213.66%ZBIOZenas BioPharma+20.79%+28.19%+30.64%+84.44%+2,050,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDXSCodexis 2.50Moderate Buy$11.00354.55% UpsideGERNGeron 2.56Moderate Buy$4.19199.11% UpsideRIGLRigel Pharmaceuticals 2.40Hold$38.20-7.60% DownsideZBIOZenas BioPharma 3.00Buy$36.6778.77% UpsideCurrent Analyst Ratings BreakdownLatest CDXS, GERN, RIGL, and ZBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/6/2025RIGLRigel PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$23.00 ➝ $32.007/10/2025GERNGeronThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSell$1.00(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDXSCodexis$59.35M3.68N/AN/A$0.82 per share2.95GERNGeron$76.99M11.60N/AN/A$0.46 per share3.04RIGLRigel Pharmaceuticals$179.28M4.14$1.08 per share38.32$0.19 per share217.58ZBIOZenas BioPharma$5M172.74N/AN/A$7.48 per share2.74Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDXSCodexis-$65.28M-$0.83N/AN/AN/A-113.67%-105.83%-46.06%10/30/2025 (Estimated)GERNGeron-$174.57M-$0.13N/AN/AN/A-53.52%-31.37%-16.01%11/6/2025 (Estimated)RIGLRigel Pharmaceuticals$17.49M$5.417.6439.37N/A36.51%438.89%57.03%11/6/2025 (Estimated)ZBIOZenas BioPharma-$156.99M-$3.55N/A∞N/AN/A-59.21%-50.56%11/11/2025 (Estimated)Latest CDXS, GERN, RIGL, and ZBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025CDXSCodexis-$0.17-$0.16+$0.01-$0.16$14.18 million$15.33 million8/12/2025Q2 2025ZBIOZenas BioPharma-$1.02-$1.25-$0.23-$1.25$5.00 millionN/A8/6/2025Q2 2025GERNGeron-$0.03-$0.02+$0.01-$0.02$47.30 million$49.04 million8/5/2025Q2 2025RIGLRigel Pharmaceuticals$1.97$3.28+$1.31$3.28$64.58 million$101.69 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCDXSCodexisN/AN/AN/AN/AN/AGERNGeronN/AN/AN/AN/AN/ARIGLRigel PharmaceuticalsN/AN/AN/AN/AN/AZBIOZenas BioPharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDXSCodexis0.715.825.70GERNGeron0.467.876.79RIGLRigel Pharmaceuticals0.462.021.90ZBIOZenas BioPharmaN/A5.235.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDXSCodexis78.54%GERNGeron73.71%RIGLRigel Pharmaceuticals66.23%ZBIOZenas BioPharmaN/AInsider OwnershipCompanyInsider OwnershipCDXSCodexis1.90%GERNGeron7.42%RIGLRigel Pharmaceuticals9.48%ZBIOZenas BioPharma16.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDXSCodexis25090.27 million88.55 millionOptionableGERNGeron70638.02 million590.68 millionOptionableRIGLRigel Pharmaceuticals16017.94 million16.24 millionOptionableZBIOZenas BioPharmaN/A42.11 million35.16 millionN/ACDXS, GERN, RIGL, and ZBIO HeadlinesRecent News About These CompaniesZenas BioPharma (NASDAQ:ZBIO) Rating Increased to Hold at Wall Street ZenSeptember 6 at 2:52 AM | americanbankingnews.comZenas BioPharma (NASDAQ:ZBIO) Trading Up 9.8% - Here's WhySeptember 4 at 2:18 PM | marketbeat.comStrategic Funding Boost: Zenas BioPharma’s Partnership with Royalty Pharma Enhances Obexelimab’s Commercial PotentialSeptember 3 at 6:30 AM | tipranks.comZenas BioPharma Secures $300M Funding for ObexelimabSeptember 2, 2025 | tipranks.comZenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 MillionSeptember 2, 2025 | globenewswire.comZenas BioPharma, Inc. $ZBIO Shares Sold by Wellington Management Group LLPAugust 31, 2025 | marketbeat.comZenas BioPharma to Present at Upcoming Healthcare Investor ConferencesAugust 26, 2025 | globenewswire.comZenas BioPharma (NASDAQ:ZBIO) Trading Down 7.2% - Here's What HappenedAugust 21, 2025 | marketbeat.comWe Think Zenas BioPharma (NASDAQ:ZBIO) Needs To Drive Business Growth CarefullyAugust 20, 2025 | finance.yahoo.comZenas BioPharma (NASDAQ:ZBIO) Trading 8.1% Higher - Should You Buy?August 20, 2025 | marketbeat.comHC Wainwright Lowers Earnings Estimates for Zenas BioPharmaAugust 17, 2025 | marketbeat.comWhat is Wedbush's Estimate for Zenas BioPharma Q3 Earnings?August 17, 2025 | marketbeat.comZenas BioPharma (NASDAQ:ZBIO) Rating Lowered to Sell at Wall Street ZenAugust 17, 2025 | marketbeat.comZenas BioPharma (ZBIO) Expected to Announce Quarterly Earnings on ThursdayAugust 15, 2025 | marketbeat.comZenas BioPharma (NASDAQ:ZBIO) Issues Earnings ResultsAugust 14, 2025 | marketbeat.comZenas BioPharma Faces Legal and Financial Challenges Amid Securities Class Action LawsuitAugust 13, 2025 | msn.comZenas BioPharma Reports Q2 2025 Financial ResultsAugust 13, 2025 | tipranks.comZenas BioPharma expects cash to fund operations into Q4 of 2026August 12, 2025 | msn.comZenas BioPharma reports Q2 EPS ($1.25) vs ($24.23) last yearAugust 12, 2025 | msn.comZenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate UpdatesAugust 12, 2025 | globenewswire.com44,067 Shares in Zenas BioPharma, Inc. (NASDAQ:ZBIO) Purchased by Jefferies Financial Group Inc.August 9, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCDXS, GERN, RIGL, and ZBIO Company DescriptionsCodexis NASDAQ:CDXS$2.42 0.00 (0.00%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$2.49 +0.07 (+2.89%) As of 09/5/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.Geron NASDAQ:GERN$1.40 +0.02 (+1.45%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$1.41 +0.01 (+0.71%) As of 09/5/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.Rigel Pharmaceuticals NASDAQ:RIGL$41.34 +1.21 (+3.02%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$41.28 -0.06 (-0.15%) As of 09/5/2025 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.Zenas BioPharma NASDAQ:ZBIO$20.51 +3.53 (+20.79%) As of 09/5/2025 04:00 PM EasternZenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
